Single Dose Safety, Tolerability And Pharmacokinetics Of Escalating Intravenous Doses Of Linezolid Followed By Evaluation Of The Effect Of Single Intravenous Doses Of Linezolid On QTc Interval In Healthy Subjects.

Trial Profile

Single Dose Safety, Tolerability And Pharmacokinetics Of Escalating Intravenous Doses Of Linezolid Followed By Evaluation Of The Effect Of Single Intravenous Doses Of Linezolid On QTc Interval In Healthy Subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 17 May 2010

At a glance

  • Drugs Linezolid; Moxifloxacin
  • Indications Bacterial infections
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors Pfizer
  • Most Recent Events

    • 10 Apr 2010 Results assessing QT interval prolongation presented at the 20th European Congress of Clinical Microbiology and Infectious Diseases.
    • 08 Apr 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 08 Apr 2009 Actual initiation date changed from Jan 2009 to Dec 2008 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top